Editorial: is hyperbaric oxygen a therapeutic opportunity for refractory perianal Crohn's disease?

Jeffrey McCurdy^{1

2}, Sylvain Boet^{2

3

4

5}, Greg Rosenfeld⁶

Affiliations

¹ Division of Gastroenterology and Hepatology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
² The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
³ Hyperbaric Medicine Unit, Department of Anesthesiology and Pain Medicine, University of Ottawa, Ottawa, ON, Canada.
⁴ Institut du Savoir Montfort, Ottawa, ON, Canada.
⁵ Faculty of Medicine, Francophone Affairs, University of Ottawa, Ottawa, ON, Canada.
⁶ Department of Gastroenterology, University of British Columbia, Vancouver, BC, Canada.

Editorial

Jeffrey McCurdy et al. Aliment Pharmacol Ther. 2021 Mar.

. 2021 Mar;53(5):667-668.

doi: 10.1111/apt.16253.

Jeffrey McCurdy^{1

2}, Sylvain Boet^{2

3

4

5}, Greg Rosenfeld⁶

¹ Division of Gastroenterology and Hepatology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
² The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
³ Hyperbaric Medicine Unit, Department of Anesthesiology and Pain Medicine, University of Ottawa, Ottawa, ON, Canada.
⁴ Institut du Savoir Montfort, Ottawa, ON, Canada.
⁵ Faculty of Medicine, Francophone Affairs, University of Ottawa, Ottawa, ON, Canada.
⁶ Department of Gastroenterology, University of British Columbia, Vancouver, BC, Canada.

No abstract available

Comment on

Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn's disease.
Lansdorp CA, Gecse KB, Buskens CJ, Löwenberg M, Stoker J, Bemelman WA, D'Haens GRAM, van Hulst RA. Lansdorp CA, et al. Aliment Pharmacol Ther. 2021 Mar;53(5):587-597. doi: 10.1111/apt.16228. Epub 2020 Dec 16. Aliment Pharmacol Ther. 2021. PMID: 33326623 Free PMC article. Clinical Trial.

1. Tandon P, Rhee GG, Schwartz D, McCurdy JD. Strategies to optimize anti-tumor necrosis factor therapy for perianal fistulizing Crohn's disease: a systematic review. Dig Dis Sci. 2019;64:3066-3077.
1. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-659, quiz 660.
1. Chapuis-Biron C, Bourrier A, Nachury M, et al. Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients. Aliment Pharmacol Ther. 2020;51:719-727.
1. Chapuis-Biron C, Kirchgesner J, Pariente B, et al. Ustekinumab for perianal Crohn's disease: the BioLAP Multicenter Study from the GETAID. Am J Gastroenterol. 2020;115:1812-1820.
1. Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281-1290.